Predictors | Overall (n=1110) | Placebo* (n=323) | 75 mg Mepolizumab* (n=317) | 100 mg Mepolizumab (n=171) | 250 mg Mepolizumab (n=150) | 750 mg Mepolizumab (n=149) |
---|---|---|---|---|---|---|
Female | 668 (60%) | 193 (60%) | 193 (61%) | 102 (60%) | 92 (61%) | 88 (59%) |
Age (years) | 49.0 (12.9) | 47.7 (13.2) | 49.8 (13.0) | 50.3 (14.5) | 49.1 (11.5) | 48.3 (11.1) |
Body Mass Index (kg/m\({}^2\)) | 28.1 (5.9) | 28.2 (5.8) | 28.0 (5.9) | 27.7 (6.0) | 28.4 (5.9) | 28.7 (5.8) |
Duration of asthma (years) | 19.3 (14.0) | 18.8 (14.3) | 19.3 (13.9) | 20.2 (12.9) | 20.4 (14.0) | 18.7 (15.0) |
Maintenance daily dose of oral corticosteroids (mg) | 4.2 (10.3) | 3.5 (8.2) | 3.7 (8.9) | 3.4 (8.3) | 6.4 (17.0) | 5.1 (10.3) |
Nasal polyps | 147 (13%) | 47 (14%) | 40 (13%) | 25 (15%) | 22 (15%) | 13 (9%) |
Percentage of predicted pre-bronchodilator FEV1 | 60.3 (17.1) | 61.1 (16.9) | 60.2 (17.5) | 59.7 (17.7) | 59.3 (16.8) | 60.7 (16.0) |
FEV1 reversibility (%) | 26.4 (21.6) | 26.7 (22.4) | 26.2 (20.2) | 28.9 (25.1) | 26.4 (21.0) | 23.4 (18.9) |
Score on asthma control questionnaire | 2.3 (1.1) | 2.3 (1.3) | 2.2 (1.1) | 2.2 (1.2) | 2.4 (1.1) | 2.2 (1.1) |
Blood eosinophil count (\(10^9/\)L) | 0.42 (0.40) | 0.44 (0.42) | 0.40 (0.38) | 0.45 (0.43) | 0.39 (0.44) | 0.36 (0.31) |
IgE (U/ml) | 447 (1093) | 435 (850) | 548 (1318) | 354 (364) | 361 (847) | 450 (1593) |
Ethnicity (Black/Hispanic) | 107 (10%) | 31 (10%) | 32 (10 %) | 16 (9%) | 14 (9%) | 14 (9%) |
History of smoking | 247 (22%) | 67 (21%) | 74 (24%) | 41 (24%) | 30 (20%) | 35 (24%) |
Exacerbations requiring admission in year prior to study | 3.6 (2.9) | 3.7 (3.3) | 3.6 (2.7) | 3.8 (2.8) | 3.4 (2.4) | 3.5 (2.9) |
Follow-up time (years) | 0.78 (0.24) | 0.75 (0.24) | 0.75 (0.24) | 0.61 (0.11) | 0.94 (0.21) | 0.92 (0.22) |
Outcomes | ||||||
Number of exacerbations (annual rate) | 1128 (1.31) | 468 (1.94) | 251 (1.05) | 86 (0.83) | 179 (1.27) | 144 (1.04) |
Duration of exacerbations (days) | 14.4 (11.6) | 15.0 (12.6) | 15.1 (13.3) | 12.9 (9.5) | 14.1 (8.5) | 12.4 (10.0) |
Number of severe exacerbations (annual rate) | 181 (0.21) | 68 (0.28) | 39 (0.16) | 14 (0.13) | 32 (0.23) | 28 (0.20) |